Systemic Metabolic Contribution From Continuous Renal Replacement Therapy (CRRT)

Quantification of Systemic Metabolic Contribution From Continuous Renal Replacement Therapy (CRRT) Utilizing Regional Citrate Anticoagulation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02998346

Enrollment

Registered

2016-12-20

Start date

2014-04-30

Completion date

2017-06-28

Last updated

2018-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Nutrition, CRRT, CVVH, citrate, anticoagulation, caloric uptake

Brief summary

The purpose of this observational study is to measure the number of calories delivered from fluids used in continuous renal replacement therapy (CRRT). We are doing this research study because the fluids used in this treatment may deliver an important number of calories. In the future this could help better estimate how much nutrition patients in the Critical Care Unit should get every day from other sources like tube feeding or nutrition through a person's veins.

Detailed description

The goal of this study is to quantify the specific metabolic contribution of standard continuous renal replacement protocols (including citrate anticoagulation) in the intensive care unit patient population at Mayo Clinic in Rochester, Minnesota utilizing a prospective, observational study. This data will allow practitioners to better tailor caloric provision with nutrition support programs, minimizing the risk of overfeeding in this complex critical care patient population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age greater than or equal to 18 years * Patients in an intensive care unit anticipated to receive greater than or equal to 24 hours of continuous venovenous hemofiltration. * Receiving regional citrate anticoagulation with ACD-A solution.

Exclusion criteria

* Vulnerable adults * Pregnant * BMI \> 40 * Patient on extracorporeal membrane oxygenation therapy * Reversal of port connections on the dialysis catheter and dialysis circuit lines

Design outcomes

Primary

Measure	Time frame
Quantify net glucose uptake from citrate and dextrose-containing fluids from continuous venovenous hemofiltration	Two days
Quantify net citrate uptake from citrate and dextrose-containing fluids from continuous venovenous hemofiltration	Two days

Outcome results